Trials / Completed
CompletedNCT04989517
Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa
A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of AT193 in the Treatment of Patients With Hidradenitis Suppurativa
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Azora Therapeutics Australia Pty Ltd · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group phase 1b study to evaluate AT193 in approximately 44 participants with HS. The treatment period will be 8 weeks followed by a 2-week nontreatment follow-up. The primary objective of this study is to evaluate the safety and tolerability of AT193. The secondary objectives of this study are to evaluate the preliminary efficacy in the treatment of HS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT193 | Topical |
Timeline
- Start date
- 2021-11-23
- Primary completion
- 2023-03-15
- Completion
- 2023-03-15
- First posted
- 2021-08-04
- Last updated
- 2024-03-15
Locations
7 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT04989517. Inclusion in this directory is not an endorsement.